Improving Patient Outcomes in Progressive Supranuclear Palsy: Evaluating the Clinical Implications of Emerging Advances for Early Diagnosis and Intervention

Released On
June 17, 2020

Expires On
June 17, 2021

Media Type

Completion Time
60 minutes

Geriatric Medicine, Neurology, Primary Care

Scroll to the Bottom of this Information to Begin this Course

Presented by Rush University Medical Center.
This activity was developed in collaboration with ASiM CE LLC.

This activity is supported by an independent educational grant from Biogen.

Credit Available

  • Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)

All other health care professionals completing this course will be issued a statement of participation.

Target Audience

This initiative is intended for internal medicine, primary care, family/general practice physicians, and others providing care to patients with PSP. No prerequisites required.

Statement of Need/Program Overview

Progressive supranuclear palsy (PSP) is an atypical parkinsonian neurodegenerative condition due to tau pathology, which is associated with significant morbidity. While symptomatic therapy for patients with PSP is available, the disease progresses over time. Unfortunately, there are no approved treatments that alter PSP disease progression. Patients experience progressive worsening of symptoms affecting ambulation, mobility, vision, speech, swallowing, and behavior over the 7- to 10-year course of the disease. This burden of untreated PSP creates an unmet clinical need for both patients and caregivers.

PSP has a broad and variable presentation, with overlapping features of other atypical parkinsonian disorders, which contributes to the difficulties in diagnosing patients. Advances in clinical diagnosis have led to revisions of the International Parkinson's and Movement Disorder Society Criteria for the Diagnosis of PSP, of which healthcare providers must be knowledgeable. Early recognition of individuals with findings suggestive of PSP is becoming increasingly important as neuroprotective treatments are under investigation. This archived presentation will provide a clinical overview of PSP – its diagnosis (including patient cases and videos), practical strategies for symptom management, patient and caregiver education, as well as a discussion of tau pathology and recent developments in investigational therapies that modify disease progression.

Learning Objectives

After participating in this activity, the participant will demonstrate the ability to:

  • RECOGNIZE the burden of cognitive, behavioral, and emotional changes as it relates to the progression of PSP.
  • EVALUATE current criteria for the early diagnosis of PSP.
  • DESCRIBE the tauopathy of PSP disease progression and the clinical efficacy of emerging targeted therapies at addressing this pathology.
  • EXPLORE current therapies for the symptomatic management of PSP and the related impact on patient quality-of-life.


Katie Kompoliti, MD

Katie Kompoliti, MD (Co-Chair)

Professor of Neurological Sciences
Movement Disorders
Rush University Medical Center
Chicago, Illinois

Jori Fleisher, MD, MSCE

Jori Fleisher, MD, MSCE (Co-Chair)

Assistant Professor, Department of Neurological Sciences
Co-Director, Lewy Body Dementia Association Research Center of Excellence
Director, CurePSP Center of Care
Section of Movement Disorders
Rush University Medical Center
Chicago, Illinois

        Nina M. Browner, MD

        Nina M. Browner, MD

        The Bryson Distinguished Associate Professor of Neurology
        Vice Chair for Education
        Director, Neurology Residency Program
        Director, Parkinson Foundation Center of Excellence
        Department of Neurology, University of North Carolina at Chapel Hill
        Chapel Hill, North Carolina


Jori Fleisher, MD, MSCE

Assistant Professor, Department of Neurological Sciences
Co-Director, Lewy Body Dementia Association Research Center of Excellence
Director, CurePSP Center of Care
Section of Movement Disorders
Rush University Medical Center
Chicago, Illinois

Accreditation Statement

In support of improving patient care, Rush University Medical Center is jointly accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE), and the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing education for the healthcare team.

Credit Designation

Rush University Medical Center designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

After reviewing this activity, participants may receive a certificate by receiving a score of 80% or higher on the CME test and completing an evaluation. A certificate of participation will be available online immediately following successful completion of the activity.


Please complete a brief preassessment before continuing with the activity. After reading the CE language and completing the preassessment, participants will watch and listen to an archived live presentation, which consists of slides synced with audio narration. Participants may receive a certificate by receiving a score of 80% or higher on the CME test and completing an evaluation. Certificates can be printed immediately online.


There is no fee for participating in this activity.

UNAPPROVED USES OF DRUGS/DEVICES – In accordance with requirements of the FDA, the audience is advised that information presented in this continuing medical education activity may contain references to unlabeled or unapproved uses of drugs or devices. Please refer to the FDA approved package insert for each drug/device for full prescribing/utilization information.

DISCLOSURES – It is the policy of the Rush University Office of Interprofessional Continuing Education to ensure that its CE activities are independent, free of commercial bias and beyond the control of persons or organizations with an economic interest in influencing the content of CE. Everyone who is in a position to control the content of an educational activity must disclose all relevant financial relationships with any commercial interest (including but not limited to pharmaceutical companies, biomedical device manufacturers, or other corporations whose products or services are related to the subject matter of the presentation topic) within the preceding 12 months.

The steering committee and participating faculty of this activity have the following relevant financial relationships to disclose.

Nina Browner, MD, MSCE
Jori Fleisher, MD, MSCE
Katie Kompliti, MD


Research Grant, Biogen; Consultant, UCB

Instructions for Participation and Credit

There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:

  1. Read the CME/CE information and faculty disclosures.
  2. Participate in the online activity.
  3. Submit the evaluation form.
Certificates will be emailed to the participant

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above



Diagnosis of PSP and Differentiation from other Atypical Parkinsonian Disorders

PSP Symptom Management

PSP Tauopathy and Emerging Targeted Therapies

Resources to Support Patients with PSP and their Caregivers

Postassessment and Evaluation